Celldex Therapeutics (CLDX)
NASDAQ:CLDX
Want to see CLDX full AI Analyst Report?
Top Page
Celldex
(NASDAQ:CLDX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$31.00
▼(-10.27% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by very weak financial performance driven by steep losses and substantial cash burn. Technicals are a supporting factor with a constructive uptrend and moderate momentum, while valuation remains constrained by negative earnings and no dividend. The recent equity raise modestly improves financial flexibility but comes with dilution risk.
Positive Factors
Low leverage / conservative balance sheet
Very low debt-to-equity (~0.4% TTM) gives Celldex durable financial flexibility, lowering near-term refinancing risk and enabling management to allocate capital to R&D or launch activities without large interest burdens. That structural strength supports runway decisions over several quarters.
Negative Factors
High cash burn and negative cash generation
Sustained operating and free cash outflows (~-$222M and -$224M TTM) indicate the business consumes material capital to advance programs. Persistent burn makes the company dependent on capital markets or partners, increasing execution risk and the probability of future dilution if clinical progress is slower than planned.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / conservative balance sheet
Very low debt-to-equity (~0.4% TTM) gives Celldex durable financial flexibility, lowering near-term refinancing risk and enabling management to allocate capital to R&D or launch activities without large interest burdens. That structural strength supports runway decisions over several quarters.
Read all positive factors
Celldex (CLDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.47B
Dividend YieldN/A
Average Volume (3M)742.09K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth-88.54%
EPS Growth-58.13%
CountryUS
Employees186
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.27
Shares Outstanding78,492,070
10 Day Avg. Volume675,230
30 Day Avg. Volume742,087
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.43
Price to Sales (P/S)1204.09
P/FCF Ratio-8.45
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue2.51K
Enterprise Value/Gross Profit-60.51K
Enterprise Value/Ebitda-6.86
Forecast
1Y Price Target
$50.71Price Target Upside46.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.35
Revenue Forecast (FY)$2.39M
Celldex Business Overview & Revenue Model
Company Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with i...
How the Company Makes Money
Celldex does not have a broad, recurring commercial product revenue base; as a clinical-stage biotech, it primarily funds operations through external financing (e.g., issuing equity and, when applicable, other capital-raising activities). Revenue,...
Celldex Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 820.00K | 1.50M | 7.02M | 6.88M | 2.36M | 4.65M |
| Gross Profit | -34.00K | 1.50M | -156.53M | -111.13M | -79.90M | -48.66M |
| EBITDA | -299.90M | -255.42M | -191.90M | -139.03M | -104.20M | -66.08M |
| Net Income | -283.69M | -258.80M | -157.86M | -141.43M | -112.33M | -70.51M |
Balance Sheet | ||||||
| Total Assets | 511.25M | 582.98M | 792.34M | 465.63M | 352.74M | 444.65M |
| Cash, Cash Equivalents and Short-Term Investments | 451.46M | 518.57M | 725.28M | 421.70M | 304.95M | 408.25M |
| Total Debt | 1.91M | 2.34M | 3.81M | 2.54M | 4.03M | 3.04M |
| Total Liabilities | 55.03M | 55.82M | 45.34M | 36.46M | 26.53M | 25.18M |
| Stockholders Equity | 456.23M | 527.16M | 747.00M | 429.17M | 326.20M | 419.48M |
Cash Flow | ||||||
| Free Cash Flow | -225.96M | -213.66M | -159.70M | -109.11M | -105.56M | -62.16M |
| Operating Cash Flow | -222.16M | -210.94M | -157.78M | -107.29M | -103.73M | -60.91M |
| Investing Cash Flow | 238.24M | 209.07M | -290.13M | -105.78M | 89.94M | -216.16M |
| Financing Cash Flow | 2.51M | 2.39M | 441.45M | 218.46M | 4.08M | 272.37M |
Celldex Technical Analysis
Neutral
34.55
Price Trends
32.23
Negative
29.47
Positive
27.51
Positive
Market Momentum
-0.44
Positive
39.67
Neutral
59.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Neutral. The current price of 34.55 is above the 20-day moving average (MA) of 31.86, above the 50-day MA of 32.23, and above the 200-day MA of 27.51, indicating a neutral trend. The MACD of -0.44 indicates Positive momentum. The RSI at 39.67 is Neutral, neither overbought nor oversold. The STOCH value of 59.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLDX.
Celldex Risk Analysis
Celldex disclosed 2 risk factors in its most recent earnings report. Celldex reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celldex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $4.39B | -193.16 | -26.79% | ― | 96.03% | 82.27% | |
52 Neutral | $2.47B | -7.07 | -50.72% | ― | -88.54% | -58.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.95B | -4.81 | -60.70% | ― | 23382.78% | 7.01% | |
47 Neutral | $889.76M | -7.89 | -11.85% | ― | 47.10% | -35.51% | |
45 Neutral | $2.55B | -6.58 | -74.86% | ― | ― | -85.06% |
* Healthcare Sector Average
CLDX
Celldex
30.14
10.17
50.93%
TVTX
Travere Therapeutics
45.04
29.52
190.21%
VRDN
Viridian Therapeutics
16.96
2.99
21.40%
VERA
Vera Therapeutics
33.94
2.20
6.93%
JANX
Janux Therapeutics Inc
14.41
-10.60
-42.38%
Celldex Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Celldex Announces Major Underwritten Public Equity Offering
Positive
Apr 2, 2026
On April 1, 2026, Celldex Therapeutics entered an underwriting agreement with Leerink Partners and TD Securities for an underwritten public offering of 10,345,000 shares of common stock at $29.00 per share, expected to raise about $282 million in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.